Drug Profile
MDR 102
Alternative Names: HLA-Mismatched LDKT; MDR-102Latest Information Update: 21 Oct 2020
Price :
$50
*
At a glance
- Originator Medeor Therapeutics
- Class Cell therapies; Haematopoietic stem cells therapies; Immunotherapies; Stem cell therapies; T lymphocyte cell therapies
- Mechanism of Action Cell replacements; Immunogenetic modulators; Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Renal transplant rejection
Most Recent Events
- 21 Oct 2020 MDR 102 is still in phase II trials for Renal transplant rejection in USA (Medeor Therapeutics pipeline, October 2020)
- 31 Jul 2020 Medeor Therapeutics plans a phase II/III trial for Renal transplant rejection (Prevention) in July 2020 (IV, Infusion) (NCT03605654)
- 11 May 2017 Medeor Therapeutics plans a phase IIb trial for Renal transplant rejection (In HLA-mismatched living donor kidney transplant recipients) in USA (Medeor Therapeutics' website, May 2017)